HKG:TCOM News 14 January 2026

January 31, 2026, 11:19 AM EST. Novartis shares trade around $114.62 after a 0.9% pullback in the past week and a 1-year return of 24.2%, lagging peers. The pharmaceutical giant boasts 70.3% returns over three years and 80% over five years. Our Discounted Cash Flow (DCF) model, projecting future cash flows until 2030, values Novartis stock at $254.07 per share, suggesting a 54.9% undervaluation versus the current price. With free cash flow projected to rise from $18.2 billion to $21.2 billion by 2030, the company's valuation looks attractive. The price-to-earnings (P/E) ratio complements this view, linking share price to earnings growth and risk. Novartis scores 5 out of 6 on undervaluation metrics, supporting the case for potential entry or hold for investors.